🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 60 of 116

  1. Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  2. Neoadjuvant Therapy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  3. Neoadjuvant therapy: TCbHPy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  4. Neoantigen specific TCR-T cell drug product

    Alaunos Therapeutics

    Gynecologic Cancer

    phase 2 mab terminated

    1 trial

  5. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  6. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  7. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    8 trials

  8. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Anatomic Stage I Breast Cancer

    phase 2 small molecule active

    1 trial

  9. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

    phase 2 small molecule terminated

    1 trial

  10. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Prostate Adenocarcinoma

    phase 2 small molecule terminated

    1 trial

  11. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2 Amplified Breast Cancer

    phase 2 small molecule completed

    1 trial

  12. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    GastroEsophageal Cancer

    phase 2 small molecule active

    1 trial

  13. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  14. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  15. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early Stage HER2+ Breast Cancer

    phase 2 small molecule completed

    1 trial

  16. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  17. Neratinib

    PUMA BIOTECHNOLOGY, INC.

    Early-stage Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial

  19. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

  20. Nimotuzumab

    Chinese University of Hong Kong

    Esophageal Cancer

    phase 2 small molecule completed

    1 trial

  21. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. Nimotuzumab + SHR-1210

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  23. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial

  24. Niraparib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  25. Niraparib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Platinum-resistant Recurrent Clear Cell Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  26. Niraparib

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    2 trials

  27. Niraparib-Bevacizumab

    Takeda

    Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

    phase 2 small molecule active

    1 trial

  28. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  29. Nivolumab

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  30. Nivolumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Biliary Tract Cancer(BTC)

    phase 2 small molecule active

    1 trial

  31. Nivolumab

    Bristol-Myers Squibb

    Prostate Cancer

    phase 2 mab completed

    1 trial

  32. Nivolumab

    Bristol-Myers Squibb

    Hepatocellular Carcinoma

    phase 2 mab completed

    1 trial

  33. Nivolumab

    Adaptive Biotechnologies Corp

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  34. Nivolumab

    United Therapeutics Europe Ltd

    Metastatic Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  35. Nivolumab & Ipilimumab

    The First People's Hospital of Lianyungang

    Lung Cancer - Non Small Cell

    phase 2 small molecule active

    1 trial

  36. Nivolumab Injection [Opdivo]

    The First People's Hospital of Lianyungang

    Neoplasms

    phase 2 small molecule active

    1 trial

  37. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  38. OBINUTUZUMAB, Zanubrutinib

    BeiGene

    Relapsed/Refractory Follicular Lymphoma

    phase 2 small molecule active

    1 trial

  39. OGX-011

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 mab completed

    1 trial

  40. OLAPARIB, BEVACIZUMAB

    The George Institute

    Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  41. OMEPRAZOLE , ACETYLSALICYLIC ACID

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  42. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  43. OMP-59R5

    Mereo BioPharma Group plc

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  44. ONDANSETRON , APREPITANT , PALONOSETRON, COMBINATIONS, PALONOSETRON , Lagipra, GRANISETRON , DEXAMETHASONE , 0.9% sodium chloride

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  45. ONO-4578

    Ono Pharmaceutical Co.,

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  46. ONO-4578, ONO-4578, BEVACIZUMAB, ONO-4578, CALCIUM FOLINATE, OXALIPLATIN, OPDIVO 10 mg/mL concentrate for solution for infusion., FLUOROURACIL

    Lacuna Pharma Pty Ltd

    PD-L1 positive advanced colorectal cancer

    phase 2 small molecule active

    1 trial

  47. OP-1250

    Olema Pharmaceuticals

    Hormone Receptor Positive Breast Carcinoma

    phase 2 small molecule completed

    1 trial

  48. OPDIVO 10 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Early stage triple negative breast cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.